Medicines Patent Pool

Medicines Patent Pool company information, Employees & Contact Information

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and the World Intellectual Property Organization (WIPO). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.
Looking for a particular Medicines Patent Pool employee's phone or email?

Medicines Patent Pool Questions

News

WHO and Medicines Patent Pool announce sublicensing agreement for rapid diagnostic test technology - World Health Organization (WHO)

WHO and Medicines Patent Pool announce sublicensing agreement for rapid diagnostic test technology World Health Organization (WHO)

Recent trends in WIPO arbitration and mediation - World Trademark Review

Recent trends in WIPO arbitration and mediation World Trademark Review

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine - GSK

Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine GSK

MPP and MSD enter into licence agreement for molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access in low- and middle- income countries - European AIDS Treatment Group

MPP and MSD enter into licence agreement for molnupiravir, an investigational oral antiviral COVID-19 medicine, to increase broad access in low- and middle- income countries European AIDS Treatment Group

Medicines Patent Pool Launches Search For Next Director - Health Policy Watch

Medicines Patent Pool Launches Search For Next Director Health Policy Watch

Policy Actions for the US Government to Accelerate Access to Oral Antivirals for COVID-19 in Low- and Middle-Income Countries - Center for Global Development

Policy Actions for the US Government to Accelerate Access to Oral Antivirals for COVID-19 in Low- and Middle-Income Countries Center for Global Development

MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission - Business Wire

MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission Business Wire

Paediatric HIV Care - ViiV Healthcare

Paediatric HIV Care ViiV Healthcare

End-to-end approach to ensuring equitable access to multipurpose prevention technologies in low- and middle-income countries - Frontiers

End-to-end approach to ensuring equitable access to multipurpose prevention technologies in low- and middle-income countries Frontiers

Antiretroviral Prices in 2023 - MSF Access

Antiretroviral Prices in 2023 MSF Access

Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis - The Lancet

Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis The Lancet

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment - Yahoo Finance

ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment Yahoo Finance

WHO and MPP announce technology transfer license to enable greater patient access to multiple essential diagnostics - World Health Organization (WHO)

WHO and MPP announce technology transfer license to enable greater patient access to multiple essential diagnostics World Health Organization (WHO)

105 countries set to receive generic versions of new Merck anti-COVID drug, molnupiravir - European AIDS Treatment Group

105 countries set to receive generic versions of new Merck anti-COVID drug, molnupiravir European AIDS Treatment Group

ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine - GSK

ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine GSK

WHO and MPP announce the first transparent, global, non-exclusive licence for a COVID-19 technology - World Health Organization (WHO)

WHO and MPP announce the first transparent, global, non-exclusive licence for a COVID-19 technology World Health Organization (WHO)

The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List - Health Policy Watch

The Medicines Patent Pool Publishes Intellectual Property Status Of 18 Drugs Added To WHO Essential Medicines List Health Policy Watch

mRNA Technology Transfer Programme moves to the next phase of its development - World Health Organization (WHO)

mRNA Technology Transfer Programme moves to the next phase of its development World Health Organization (WHO)

New agreement under C-TAP aims to improve global access to COVID-19 testing technologies - World Health Organization (WHO)

New agreement under C-TAP aims to improve global access to COVID-19 testing technologies World Health Organization (WHO)

Turning the promise of multipurpose prevention technologies into a market reality: a commentary - Frontiers

Turning the promise of multipurpose prevention technologies into a market reality: a commentary Frontiers

Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic - Frontiers

Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic Frontiers

UNAIDS welcomes the announcement by Medicines Patent Pool (MPP) and ViiV of three licenses signed with generic manufacturers for long-acting PrEP, and urges further urgent action by ViiV - UNAIDS

UNAIDS welcomes the announcement by Medicines Patent Pool (MPP) and ViiV of three licenses signed with generic manufacturers for long-acting PrEP, and urges further urgent action by ViiV UNAIDS

MSF: Merck and Medicines Patent Pool license for new COVID-19 drug molnupiravir doesn’t go far enough - Doctors Without Borders

MSF: Merck and Medicines Patent Pool license for new COVID-19 drug molnupiravir doesn’t go far enough Doctors Without Borders

MSF response to license between Pfizer and Medicines Patent Pool for new COVID-19 treatment Paxlovid - MSF Access

MSF response to license between Pfizer and Medicines Patent Pool for new COVID-19 treatment Paxlovid MSF Access

Civil society and medical product access in Africa: Lessons from COVID-19 - Frontiers

Civil society and medical product access in Africa: Lessons from COVID-19 Frontiers

Cipla and Mylan have applied for prequalification of dolutegravir - Life4me+

Cipla and Mylan have applied for prequalification of dolutegravir Life4me+

Full article: Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study - Taylor & Francis Online

Full article: Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study Taylor & Francis Online

Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection - ScienceDirect.com

Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection ScienceDirect.com

The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development - Frontiers

The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development Frontiers

Editorial: World AIDS Day 2022: putting ourselves to the test: achieving equity to end HIV - Frontiers

Editorial: World AIDS Day 2022: putting ourselves to the test: achieving equity to end HIV Frontiers

Progress, impacts and lessons from market shaping in the past decade: a systematic review - Frontiers

Progress, impacts and lessons from market shaping in the past decade: a systematic review Frontiers

In Axing mRNA Contract, Trump Delivers Another Blow to US Biosecurity, Former Officials Say - KFF Health News

In Axing mRNA Contract, Trump Delivers Another Blow to US Biosecurity, Former Officials Say KFF Health News

Towards affordable CRISPR genomic therapies: a task force convened by the Innovative Genomics Institute - Nature

Towards affordable CRISPR genomic therapies: a task force convened by the Innovative Genomics Institute Nature

New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency - Health GAP

New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency Health GAP

Interview With Charles Gore, Medicines Patent Pool Executive Director - Intellectual Property Watch

Interview With Charles Gore, Medicines Patent Pool Executive Director Intellectual Property Watch

UNAIDS welcomes landmark agreement between Medicines Patent Pool and Merck Sharp and Dohme - UNAIDS

UNAIDS welcomes landmark agreement between Medicines Patent Pool and Merck Sharp and Dohme UNAIDS

Gilead Makes a Splash: Dives Deep Into the Patent Pool and Comes Up With a Pill - Forbes

Gilead Makes a Splash: Dives Deep Into the Patent Pool and Comes Up With a Pill Forbes

Patent pooling: A way forward to circumvent tussle between patent owners - Times of India

Patent pooling: A way forward to circumvent tussle between patent owners Times of India

Pathways to ensure universal and affordable access to hepatitis C treatment - BMC Medicine

Pathways to ensure universal and affordable access to hepatitis C treatment BMC Medicine

BIO FARMA, WHO, MPP and CEPI COLLABORATE TO INCREASE VACCINE ACCESSIBILITY IN THE GLOBAL SOUTH REGION - biofarma.co.id

BIO FARMA, WHO, MPP and CEPI COLLABORATE TO INCREASE VACCINE ACCESSIBILITY IN THE GLOBAL SOUTH REGION biofarma.co.id

Top Medicines Patent Pool Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant